Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
Investors are piling into gold, sending the precious metal to a six-year high, and analysts think the commodity has established a base to go even higher.Marketsread more
Apple's iOS 13 is coming this fall, but you can already try it on your iPhone with the new public beta. Here are some of the best hidden features.Technologyread more
The Conference Board, a business research group, on Tuesday released the June update for its consumer confidence index.Economyread more
Massachusetts Institute of Technology President L. Rafael Reif warned the MIT community of "serious long-term costs" to in an email to the school community Tuesday.Technologyread more
These are the stocks posting the largest moves midday.Market Insiderread more
The yield on the benchmark 10-year Treasury note falls below 2% as investors look for safety following the release of much weaker-than-expected confidence data.Bondsread more
Trump slams Iran on Twitter for issuing a "very ignorant and insulting statement" after the U.S. slapped fresh sanctions on Tehran.Politicsread more
Florida patients with serious conditions such as post-traumatic stress disorder are increasingly opting for medical cannabis over opioids, the CEO of the state's first and largest fully licensed medical marijuana company told CNBC on Monday.
"We're seeing a huge transition," Kim Rivers, the CEO of Trulieve, told "Mad Money" host in an exclusive interview. "That's actually one of our initiatives in front of the [Florida state] legislature this upcoming session, to introduce policies to say instead of only having opioids as an alternative, why not medical cannabis?"
With over 80,000 patients and 17 retail locations in Florida, Trulieve offers 90 cannabis-based products that help treat a range of health problems, including seizure conditions, cancer and AIDS. A bulk of Trulieve's patients also suffer from PTSD, given Florida's large veteran population, Rivers said.
The company, which is vertically integrated and thus cultivates, manufactures and distributes its own products, makes products with varying levels of both THC and CBD, marijuana's main active compounds.
And with its position as Florida's top medical cannabis producer, Trulieve is on the front lines of helping cannabis-based alternatives to opiates become more mainstream, Rivers told Cramer.
"There have been a number of recent studies that have come out that have shown that in states where medical cannabis programs are robust, the number of opioid prescriptions reduces dramatically," the CEO said.
"We also know from just firsthand true stories, which we have on our website every Tuesday, that a number of our patients are transitioning from opioids to medical cannabis very effectively, and it's a much safer and effective alternative," she continued.
In a move becoming commonplace among cannabis producers, Trulieve went public in Canada via a reverse takeover with a former mining company, which Rivers described as a limited-liability "shell" that Trulieve now owns.
"There are some complications with being a cannabis company in the United States and having primary operations in the United States. So an RTO was the way that we needed to go," she said, adding that "we're very comfortable that that is a clean shell that we now own."
And while Trulieve's license in Florida prevents the company from expanding to other states, its newly public status has opened some doors for the medical cannabis cultivator.
"We are looking to go elsewhere," Rivers told Cramer. "And we can't go elsewhere now with our current license in Florida, so we would need to make acquisitions, which is one of the reasons and one of the main drivers that we decided to go public a couple weeks ago."
Correction: This story has been updated to reflect that Trulieve makes an assortment of products with varying levels of THC and CBD.